<DOC>
	<DOCNO>NCT00684853</DOCNO>
	<brief_summary>The purpose study determine association bevacizumab PDT safety effective treatment exudative AMD</brief_summary>
	<brief_title>Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab Treat Exudative AMD</brief_title>
	<detailed_description>Exudative AMD leader blind people 60 year . The best treatment disease today monthly injection anti-VEGF vitreous cavity increase chance get endophthalmites . The participant study randomize 1:1 ration one two study group : single therapy bevacizumab ( 3 injection 3 month ) association bevacizumab ( 3 injection 3 month ) full fluence PDT ( single baseline ) . All bevacizumab injection contain 1.25g drug administrate every month 3 continuos month . After randomization , participant return clinic approximately every four week 4 month study assessment possible re-treatment ( necessary ) . Participants return clinic week 20 final study assessment . Study assessment include : visual acuity , optical coherence tomography fundus photography .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>iqual 50 year old male female Choroidal neovascularization sub foveal fovea secondary AMD ( Predominantly Classic , Minimally Classic , Occult lesion acceptable ) Greatest linear dimension ( GLD ) entire lesion &lt; 5400 Âµm ( read center confirmation require ) ETDRS best correct visual acuity 20/40 20/320 ( 73 24 letter score ) Total area lesion must &lt; 9 MPS DA pretreatment ETDRS best correct visual acuity well 34 letter macular surgery history laser photocoagulation study eye within 30 dais eye surgery within 30 day history notreat glaucoma acuite uveits history endophthalmites vitreous hemorrhage geographic atrophy fibrosis correspond &gt; 50 % lesion</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>PDT</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Full fluence</keyword>
	<keyword>exudative</keyword>
	<keyword>CNV</keyword>
	<keyword>Drusen</keyword>
	<keyword>ARMD</keyword>
	<keyword>Vetaporfin</keyword>
	<keyword>efficacy</keyword>
	<keyword>treatment</keyword>
</DOC>